Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Turco

Showing results (41-50 of 82) with videos related to

Pageof 9
Sort By:
Cancers|April 26, 2025
Metastasis-Directed Therapy in Oligometastatic Prostate Cancer: Biological Rationale and Systematic Review of Published DataFrancesco Fiorica, Teodoro Sava, Jacopo Giuliani, et al.
Cancers|April 12, 2022
Prostate Cancer and Sleep Disorders: A Systematic ReviewDavide Sparasci, Ilenia Napoli, Lorenzo Rossi, et al.
Minerva Urology and Nephrology|March 30, 2021
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamideChiara Pisano, Marcello Tucci, Rosario F DI Stefano, et al.
Minerva Urology and Nephrology|February 11, 2022
Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective studyTiziana Angusti, Rosario F DI Stefano, Antonella Parente, et al.
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology|April 15, 2020
Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamideConsuelo Buttigliero, Marcello Tucci, Cristina Sonetto, et al.
Cells|May 28, 2022
Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?Marco Audisio, Consuelo Buttigliero, Fabio Turco, et al.
Clinical Genitourinary Cancer|November 30, 2024
Testing BRCA 1-2 Mutations in Metastatic Prostate Cancer: Results of a Survey of the Italian Association of Medical OncologyIsabella Saporita, Mariangela Calabrese, Stefano Poletto, et al.
International Journal of Molecular Sciences|January 11, 2024
Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate CancerMariangela Calabrese, Isabella Saporita, Fabio Turco, et al.
Cancer Communications (London, England)|July 22, 2022
Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapyFabio Turco, Marcello Tucci, Marco Donatello Delcuratolo, et al.
Inflammatory Bowel Diseases|July 15, 2016
Molecular Signaling and Dysfunction of the Human Reactive Enteric Glial Cell Phenotype: Implications for GI Infection, IBD, POI, Neurological, Motility, and GI DisordersAndromeda Liñán-Rico, Fabio Turco, Fernando Ochoa-Cortes, et al.
Pageof 9

Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Cancers|April 26, 2025
Metastasis-Directed Therapy in Oligometastatic Prostate Cancer: Biological Rationale and Systematic Review of Published DataFrancesco Fiorica, Teodoro Sava, Jacopo Giuliani, et al.
Cancers|April 12, 2022
Prostate Cancer and Sleep Disorders: A Systematic ReviewDavide Sparasci, Ilenia Napoli, Lorenzo Rossi, et al.
Minerva Urology and Nephrology|March 30, 2021
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamideChiara Pisano, Marcello Tucci, Rosario F DI Stefano, et al.
Minerva Urology and Nephrology|February 11, 2022
Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective studyTiziana Angusti, Rosario F DI Stefano, Antonella Parente, et al.
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology|April 15, 2020
Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamideConsuelo Buttigliero, Marcello Tucci, Cristina Sonetto, et al.
Cells|May 28, 2022
Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?Marco Audisio, Consuelo Buttigliero, Fabio Turco, et al.
Clinical Genitourinary Cancer|November 30, 2024
Testing BRCA 1-2 Mutations in Metastatic Prostate Cancer: Results of a Survey of the Italian Association of Medical OncologyIsabella Saporita, Mariangela Calabrese, Stefano Poletto, et al.
International Journal of Molecular Sciences|January 11, 2024
Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate CancerMariangela Calabrese, Isabella Saporita, Fabio Turco, et al.
Cancer Communications (London, England)|July 22, 2022
Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapyFabio Turco, Marcello Tucci, Marco Donatello Delcuratolo, et al.
Inflammatory Bowel Diseases|July 15, 2016
Molecular Signaling and Dysfunction of the Human Reactive Enteric Glial Cell Phenotype: Implications for GI Infection, IBD, POI, Neurological, Motility, and GI DisordersAndromeda Liñán-Rico, Fabio Turco, Fernando Ochoa-Cortes, et al.
Pageof 9